Thursday, September 17, 2026RSS
Peptide.Wire

The daily wire on therapeutic peptides. Regulatory, research, compounding and the incretin race, condensed.

Researchalzheimersmonoclonal antibodiescochrane

Cochrane review of amyloid-beta antibodies appraised for neurologists

Neurological Sciences summarizes Cochrane evidence on amyloid-targeting monoclonal antibodies in early Alzheimer's disease.

PR
By Priya Raman · Science Reporter
Sep 16 20:00 ETSource: Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology

The wire

  1. 01Authors summarized and appraised a Cochrane review of amyloid-beta-targeting monoclonal antibodies in early Alzheimer's disease.
  2. 02Aimed at guiding neurologists weighing use of the antibody class.
  3. 03Excerpt does not state the review's conclusions on benefit or harm.

From the source

Amyloid-beta-targeting monoclonal antibodies in early Alzheimer's disease: a cochrane review summary and appraisal for the neurological community

Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2026 Sep 17 · Santos DH, da Silva AMP et al.

Read at pubmed.ncbi.nlm.nih.gov
Source URL https://pubmed.ncbi.nlm.nih.gov/42752707/